Literature DB >> 34850269

The impact of surgical downgrading on prostate cancer recurrence: systematic review and analysis of a multiethnic population.

Denzel Zhu1, William Shyr1, Michelle Toker1, Ethan Fram2, Jinrong Cheng1,3, Evan Z Kovac1,2, Ilir Agalliu2,4, Ahmed Aboumohamed1,2, Kara L Watts5,6.   

Abstract

OBJECTIVE: To perform a systematic review and a retrospective cohort analysis evaluating the rates of surgical downgrading of prostate cancer (PCa) from biopsy (PBx) to radical prostatectomy (RP), and their association with biochemical recurrence (BCR) in a multiethnic population.
METHODS: A systematic review of PubMed and other databases was performed. We included retrospective studies evaluating the relationship between surgical downgrading and BCR-free survival. Data regarding Gleason score (GL) downgrading were abstracted from the articles and categorized as follows: GL8-10 to GL7, GL7 to GL6, and GL 7(4 + 3) to GL7(3 + 4). We also performed a retrospective cohort review of patients who underwent RP at our institution from 2005 through 2020. Kaplan-Meier survival analysis and Cox proportional hazards models were used to compare BCR among downgraded versus non-downgraded men.
RESULTS: Systematic review yielded 137 abstracts; of these, 36 full-texts were reviewed, 8 of which were included in our systematic review. Despite substantial variability, all showed that GL at RP is one of the most important factors of BCR-free survival. A total of 1,484 men with PCa were analyzed from our institution. On multivariate analysis, GL7 to GL6 downgrading (HR = 0.50, p = 0.022) and GL8-10 to GL7 downgrading (HR = 0.42, p = 0.011) were associated with reduced risk of BCR when compared to men with GL7 and GL8-10 concordance, respectively. However, GL7(4 + 3) to GL7(3 + 4) downgrading was not significantly associated with reduced BCR (HR = 0.56, p = 0.12), when compared to GL7(4 + 3) concordance, although HR was similar.
CONCLUSION: Surgical downgrading at RP was associated with a reduced risk of BCR compared to GL concordant disease, and these findings have been validated within our multiethnic population. Pathologic downgrading at the time of RP may be a more useful predictor of subsequent BCR in comparison to that associated with GL concordant pathology.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biochemical recurrence; Hispanic; Multiethnic; Non-Hispanic black; Non-Hispanic white; Prostate biopsy; Prostate cancer; Radical prostatectomy; Surgical downgrading; Systematic review

Mesh:

Substances:

Year:  2021        PMID: 34850269     DOI: 10.1007/s00345-021-03892-2

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  21 in total

1.  Democratizing information creation from health care data for quality improvement, research, and education-the Montefiore Medical Center Experience.

Authors:  Eran Bellin; David D Fletcher; Noah Geberer; Shahidul Islam; Navneet Srivastava
Journal:  Acad Med       Date:  2010-08       Impact factor: 6.893

2.  Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate.

Authors:  Mark L Gonzalgo; Patrick J Bastian; Leslie A Mangold; Bruce J Trock; Jonathan I Epstein; Patrick C Walsh; Alan W Partin
Journal:  Urology       Date:  2006-01       Impact factor: 2.649

3.  The prognostic impact of downgrading and upgrading from biopsy to radical prostatectomy among men with Gleason score 7 prostate cancer.

Authors:  Won Sik Jang; Dong Hoon Koh; Jongchan Kim; Jong Soo Lee; Doo Yong Chung; Won Sik Ham; Koon Ho Rha; Young Deuk Choi
Journal:  Prostate       Date:  2019-09-04       Impact factor: 4.104

4.  Racial disparities in oncologic outcomes after radical prostatectomy: long-term follow-up.

Authors:  Farzana A Faisal; Debasish Sundi; John L Cooper; Elizabeth B Humphreys; Alan W Partin; Misop Han; Ashley E Ross; Edward M Schaeffer
Journal:  Urology       Date:  2014-12       Impact factor: 2.649

5.  Patient Characteristics at Prostate Cancer Diagnosis in Different Races at an Academic Center Serving a Diverse Population.

Authors:  Tejas Suresh; Janaki Sharma; Sanjay Goel; Evan Kovac; Qi Gao; Benjamin Gartrell
Journal:  Clin Genitourin Cancer       Date:  2018-12-13       Impact factor: 2.872

6.  Prognostic significance of Gleason score discrepancies between needle biopsy and radical prostatectomy.

Authors:  Michael Müntener; Jonathan I Epstein; David J Hernandez; Mark L Gonzalgo; Leslie Mangold; Elizabeth Humphreys; Patrick C Walsh; Alan W Partin; Matthew E Nielsen
Journal:  Eur Urol       Date:  2007-11-20       Impact factor: 20.096

7.  Comparing the Gleason prostate biopsy and Gleason prostatectomy grading system: the Lahey Clinic Medical Center experience and an international meta-analysis.

Authors:  Michael S Cohen; Robert S Hanley; Teodora Kurteva; Robin Ruthazer; Mark L Silverman; Andrea Sorcini; Karim Hamawy; Robert A Roth; Ingolf Tuerk; John A Libertino
Journal:  Eur Urol       Date:  2008-03-28       Impact factor: 20.096

8.  Prostate cancer upgrading or downgrading of biopsy Gleason scores at radical prostatectomy: prediction of "regression to the mean" using routine clinical features with correlating biochemical relapse rates.

Authors:  Muammer Altok; Patricia Troncoso; Mary F Achim; Surena F Matin; Graciela N Gonzalez; John W Davis
Journal:  Asian J Androl       Date:  2019 Nov-Dec       Impact factor: 3.285

9.  Pathological upgrading in prostate cancer treated with surgery in the United Kingdom: trends and risk factors from the British Association of Urological Surgeons Radical Prostatectomy Registry.

Authors:  Nicholas Bullock; Andrew Simpkin; Sarah Fowler; Murali Varma; Howard Kynaston; Krishna Narahari
Journal:  BMC Urol       Date:  2019-10-17       Impact factor: 2.264

View more
  2 in total

1.  Prostate cancer upgrading and adverse pathology in Hispanic men undergoing radical prostatectomy.

Authors:  Helen Y Hougen; Oleksii A Iakymenko; Sanoj Punnen; Chad R Ritch; Bruno Nahar; Dipen J Parekh; Oleksandr N Kryvenko; Mark L Gonzalgo
Journal:  World J Urol       Date:  2022-06-10       Impact factor: 3.661

2.  Incidental prostate cancer after holmium laser enucleation of the prostate: incidence and predictive factors for clinical progression.

Authors:  Clément Klein; Thibault Marquette; Grégoire Capon; Mokrane Yacoub; Eric Alezra; Jean-Christophe Bernhard; Franck Bladou; Grégoire Robert
Journal:  Int J Clin Oncol       Date:  2022-03-25       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.